COLL
Collegium Pharmaceutical, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
21.75
▼ 0.12 (0.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
22.20
Prev close
21.87
Day high
22.32
Day low
21.68
Volume
634.06K
Market cap
$712.32M
P/E (TTM)
17.23
52W range
21.43 – 50.79
Day trading desk
Gap from prior close
+1.51%
Prior close 21.87
VWAP
21.98
-1.03% from price
Relative volume
0.66×
Normal
Session range
14.35%
20.00 – 22.87
Position in range
61%
Mid range
ATR (14D)
0.85
3.90% of price
Prior day high
22.25
PDH
Prior day low
21.67
PDL
Bid / ask spread
—
Quote not published
Session volume
491.41K
Avg 744.74K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.57%
-3.5%
1M
-7.01%
-8.2%
3M
-38.93%
-43.5%
6M
-33.21%
-51.4%
YTD
-52.74%
-67.0%
1Y
-36.78%
-53.2%
3Y
-2.10%
-84.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on COLL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+78.68K
Net buying
Buy transactions
10
96.03K shares
Sell transactions
4
17.35K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
374.39K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 8, 26 | SANTINI GINO Director |
CONVERSION | 8.70K | $143.46K | Direct |
| May 18, 26 | FREUND JOHN GORDON Director |
SELL | 20 | $681 | Direct |
| May 15, 26 | FREUND JOHN GORDON Director |
SELL | 4.13K | $142.55K | Direct |
| May 15, 26 | FREUND JOHN GORDON Director |
CONVERSION | 8.70K | $143.46K | Direct |
| May 14, 26 | SANTINI GINO Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | BOHLIN GAREN G. Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | FREUND JOHN GORDON Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | LURKER NANCY S Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | PAYA CARLOS V Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | BALICE-GORDON RITA J Director |
STOCK | 8.74K | $0 | Direct |
| May 14, 26 | DONOVAN MICHAEL Director |
STOCK | 17.48K | $0 | Direct |
| May 13, 26 | LURKER NANCY S Director |
SELL | 4.50K | $161.86K | Direct |
| May 11, 26 | BOHLIN GAREN G. Director |
SELL | 8.70K | $323.49K | Direct |
| May 11, 26 | BOHLIN GAREN G. Director |
CONVERSION | 8.70K | $143.46K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOHLIN GAREN G. |
Director | 71.00K | Stock Award(Grant) |
DIETER DAVID |
General Counsel | 77.07K | Sale |
DREYER SCOTT |
Officer | 71.77K | Sale |
FREUND JOHN GORDON |
Director | 115.71K | Sale |
KARNANI VIKRAM |
Chief Executive Officer | 197.86K | Stock Award(Grant) |
KUHLMANN SHIRLEY R. |
General Counsel | 108.14K | Sale |
RUBRIC CAPITAL MANAGEMENT L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SANTINI GINO |
Director | 112.48K | Conversion of Exercise of derivative security |
SMITH THOMAS BRAIN M.D. |
Officer | 90.65K | Stock Award(Grant) |
TUPPER COLLEEN |
Chief Financial Officer | 147.28K | Stock Award(Grant) |
Fundamentals
Market cap$712.32M
Enterprise value$1.80B
Revenue (TTM)$808.21M
Gross profit$722.93M
EBITDA$405.26M
Net income$47.91M
EPS (TTM)$1.27
Free cash flow$324.04M
Total cash$129.47M
Total debt$1.22B
Book value / share$9.60
Shares outstanding32.56M
Float30.35M
Short % of float20.82%
Dividend yield0.00%
Beta (5Y)0.73
Valuation & profitability ratios
Trailing P/E17.23
Forward P/E3.29
PEG ratio0.64
Price / sales—
Price / book2.28
EV / revenue2.23
EV / EBITDA4.44
Gross margin89.45%
Operating margin5.65%
Profit margin5.93%
Return on equity17.61%
Return on assets5.76%
Debt / equity390.46
Current ratio1.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $780.57M | $631.45M | $566.77M | $463.93M | — | +23.6% |
| Operating revenue | $780.57M | $631.45M | $566.77M | $463.93M | — | +23.6% |
| Cost of revenue | $317.31M | $254.10M | $240.60M | $254.44M | — | +24.9% |
| Gross profit | $463.26M | $377.34M | $326.17M | $209.49M | — | +22.8% |
| Research & development | — | $0 | $0 | $3.98M | $9.45M | — |
| Selling, general & admin | $284.80M | $210.36M | $159.21M | $172.19M | — | +35.4% |
| Total operating expense | $284.80M | $210.36M | $159.21M | $176.17M | — | +35.4% |
| Operating income | $178.45M | $166.98M | $166.96M | $33.32M | — | +6.9% |
| Net interest income | -$71.02M | -$60.00M | -$67.72M | -$62.17M | — | -18.4% |
| Pre-tax income | $92.62M | $98.57M | $75.73M | -$28.85M | — | -6.0% |
| Tax provision | $29.75M | $29.38M | $27.58M | -$3.85M | — | +1.3% |
| Net income | $62.87M | $69.19M | $48.16M | -$25.00M | — | -9.1% |
| Net income to common | $62.87M | $69.19M | $48.16M | -$25.00M | — | -9.1% |
| Basic EPS | 1.98 | 2.14 | 1.43 | -0.74 | — | -7.5% |
| Diluted EPS | 1.73 | 1.86 | 1.29 | -0.74 | — | -7.0% |
| EBIT | $174.93M | $172.54M | $159.07M | $34.37M | — | +1.4% |
| EBITDA | $401.00M | $341.70M | $308.33M | $173.31M | — | +17.4% |
| Basic shares | 31.71M | 32.27M | 33.74M | 33.83M | — | -1.8% |
| Diluted shares | 39.70M | 40.42M | 41.79M | 33.83M | — | -1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $231.25M | $70.56M | $238.95M | $173.69M | +227.7% |
| Cash & short-term investments | $386.68M | $162.76M | $310.55M | $173.69M | +137.6% |
| Accounts receivable | $211.33M | $228.54M | $179.53M | $183.12M | -7.5% |
| Inventory | $40.91M | $35.56M | $32.33M | $46.50M | +15.1% |
| Total current assets | $691.41M | $482.26M | $537.60M | $419.99M | +43.4% |
| Property, plant & equipment | $16.20M | $20.15M | $22.01M | $26.38M | -19.6% |
| Goodwill & intangibles | $815.43M | $1.05B | $555.57M | $701.16M | -22.6% |
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | -0.4% |
| Total current liabilities | $440.03M | $509.51M | $457.92M | $433.73M | -13.6% |
| Current debt | $29.00M | $64.58M | $183.33M | $162.50M | -55.1% |
| Long-term debt | $780.33M | $787.90M | $483.84M | $538.45M | -1.0% |
| Total debt | $814.86M | $859.30M | $674.28M | $709.17M | -5.2% |
| Total liabilities | $1.36B | $1.43B | $947.88M | $979.29M | -5.5% |
| Retained earnings | -$101.13M | -$164.00M | -$233.19M | -$281.34M | +38.3% |
| Shareholder equity | $301.68M | $228.84M | $195.43M | $194.84M | +31.8% |
| Working capital | $251.38M | -$27.25M | $79.69M | -$13.74M | +1,022.4% |
| Net tangible assets | -$513.76M | -$824.89M | -$360.13M | -$506.32M | +37.7% |
| Shares issued | 40.74M | 39.65M | 38.19M | 37.08M | +2.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $62.87M | $69.19M | $48.16M | -$25.00M | -9.1% |
| Depreciation & amortisation | $226.07M | $169.16M | $149.26M | $138.94M | +33.6% |
| Stock-based compensation | $41.91M | $32.40M | $27.14M | $22.87M | +29.3% |
| Change in working capital | $3.76M | -$54.98M | $21.73M | -$12.71M | +106.8% |
| Operating cash flow | $329.32M | $204.98M | $274.75M | $124.23M | +60.7% |
| Capital expenditure | -$1.74M | -$1.65M | -$461.00K | -$1.62M | -5.3% |
| Investing cash flow | -$63.53M | -$287.76M | -$70.81M | -$573.69M | +77.9% |
| Share buybacks | -$25.10M | -$60.02M | -$75.00M | -$14.06M | +58.2% |
| Financing cash flow | -$110.25M | -$60.60M | -$140.18M | $436.72M | -81.9% |
| Free cash flow | $327.58M | $203.33M | $274.29M | $122.61M | +61.1% |
| End cash position | $252.16M | $96.61M | $239.99M | $176.24M | +161.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $199.88M | $193.52M | $205.45M | $209.36M | $188.00M | +3.3% |
| Operating revenue | $199.88M | $193.52M | $205.45M | $209.36M | $188.00M | +3.3% |
| Cost of revenue | $89.59M | $76.27M | $77.07M | $80.19M | $79.62M | +17.5% |
| Gross profit | $110.29M | $117.25M | $128.38M | $129.17M | $108.38M | -5.9% |
| Selling, general & admin | $106.59M | $86.35M | $67.64M | $67.10M | $73.64M | +23.4% |
| Total operating expense | $106.59M | $86.35M | $67.64M | $67.10M | $73.64M | +23.4% |
| Operating income | $3.70M | $30.90M | $60.74M | $62.07M | $34.75M | -88.0% |
| Net interest income | -$17.23M | -$12.16M | -$15.73M | -$18.65M | -$18.08M | -41.7% |
| Pre-tax income | -$13.53M | $18.74M | $29.04M | $43.44M | $17.02M | -172.2% |
| Tax provision | $1.52M | $4.24M | $12.07M | $11.93M | $5.04M | -64.2% |
| Net income | -$15.05M | $14.50M | $16.96M | $31.51M | $11.98M | -203.8% |
| Net income to common | -$15.05M | $14.50M | $16.96M | $31.51M | $11.98M | -203.8% |
| Basic EPS | -0.46 | 0.45 | 0.54 | 1.00 | 0.38 | -202.2% |
| Diluted EPS | -0.46 | 0.40 | 0.46 | 0.84 | 0.34 | -215.0% |
| EBIT | $5.99M | $34.60M | $48.33M | $65.20M | $37.49M | -82.7% |
| EBITDA | $70.75M | $90.54M | $104.72M | $121.71M | $94.10M | -21.9% |
| Basic shares | 32.46M | 32.09M | 31.65M | 31.57M | 31.81M | +1.2% |
| Diluted shares | 32.46M | 40.07M | 40.08M | 39.44M | 39.08M | -19.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $129.47M | $268.65M | $231.25M | $150.10M | $117.35M | -51.8% |
| Cash & short-term investments | $129.47M | $421.75M | $386.68M | $285.86M | $222.15M | -69.3% |
| Accounts receivable | $285.10M | $228.76M | $211.33M | $233.95M | $213.02M | +24.6% |
| Inventory | $113.27M | $42.74M | $40.91M | $38.05M | $38.15M | +165.0% |
| Total current assets | $608.01M | $745.67M | $691.41M | $613.87M | $549.21M | -18.5% |
| Property, plant & equipment | $14.44M | $15.64M | $16.20M | $16.68M | $18.17M | -7.6% |
| Goodwill & intangibles | $1.38B | $759.96M | $815.43M | $870.91M | $928.39M | +81.1% |
| Total assets | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | +29.3% |
| Total current liabilities | $589.86M | $434.97M | $440.03M | $452.93M | $464.61M | +35.6% |
| Current debt | $55.00M | $32.63M | $29.00M | $64.58M | $64.58M | +68.6% |
| Long-term debt | $1.04B | $770.20M | $780.33M | $743.53M | $758.34M | +34.6% |
| Total debt | $1.10B | $808.06M | $814.86M | $813.99M | $829.11M | +35.7% |
| Total liabilities | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | +36.2% |
| Retained earnings | -$101.68M | -$86.63M | -$101.13M | -$118.09M | -$149.60M | -17.4% |
| Shareholder equity | $311.91M | $312.42M | $301.68M | $274.81M | $232.21M | -0.2% |
| Working capital | $18.15M | $310.69M | $251.38M | $160.94M | $84.60M | -94.2% |
| Net tangible assets | -$1.06B | -$447.54M | -$513.76M | -$596.10M | -$696.19M | -137.8% |
| Shares issued | 32.50M | 41.44M | 40.74M | 40.63M | 40.45M | -21.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.05M | $14.50M | $16.96M | $31.51M | $11.98M | -203.8% |
| Depreciation & amortisation | $64.77M | $55.94M | $56.40M | $56.51M | $56.61M | +15.8% |
| Stock-based compensation | $14.48M | $10.88M | $9.75M | $9.81M | $10.82M | +33.1% |
| Change in working capital | $13.60M | -$23.85M | $33.83M | -$8.50M | -$5.86M | +157.0% |
| Operating cash flow | $71.32M | $57.11M | $123.05M | $78.44M | $72.44M | +24.9% |
| Capital expenditure | -$496.00K | -$270.00K | -$689.00K | -$188.00K | -$65.00K | -83.7% |
| Investing cash flow | -$502.59M | $1.63M | -$20.07M | -$30.87M | -$2.92M | -30,990.7% |
| Share buybacks | — | — | $0 | $0 | — | — |
| Financing cash flow | $292.09M | -$21.34M | -$21.82M | -$14.82M | -$48.37M | +1,468.6% |
| Free cash flow | $70.83M | $56.84M | $122.36M | $78.25M | $72.37M | +24.6% |
| End cash position | $150.38M | $289.56M | $252.16M | $171.00M | $138.25M | -48.1% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
22.50
+2.8% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
242
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
25.00
0 contracts
Heaviest put OI
22.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.77 | 1.92 | +8.8% |
| Mar 2026 | 1.52 | 1.76 | +15.5% |
| Dec 2025 | 2.14 | 2.04 | -4.7% |
| Sep 2025 | 1.86 | 2.25 | +21.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.80 | 7 | $217.28M | +3.8% |
| Next quarter | 1.91 | 7 | $224.84M | +9.4% |
| Current year | 7.34 | 7 | $835.61M | +7.0% |
| Next year | 6.65 | 7 | $846.55M | +1.3% |
Analyst targets & ownership
Mean target$49.00
High target$60.00
Low target$43.00
Implied upside125.29%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy2 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders1.15%
Held by institutions131.04%
Institutions holding382
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
22.19
-1.99% from price
SMA 20
22.44
-2.48% from price
SMA 50
26.22
-16.54% from price
SMA 100
30.43
-28.52% from price
SMA 200
35.48
-38.33% from price
EMA 12
22.27
-2.34% from price
EMA 26
23.41
-7.08% from price
EMA 50
25.73
-15.46% from price
RSI (14)
30.1
Neutral
MACD (12,26,9)
-1.14
Hist 0.22
ATR (14)
0.85
3.88% of price
Realised vol 30D
26.6%
Annualised
Bollinger upper
23.33
20, 2σ
Bollinger lower
21.54
20, 2σ
50 / 200 cross
Death
26.22 vs 35.48
Trend bias
Below 200
-38.33%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.38
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
26.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-56.2%
Peak to trough
Max drawdown 5Y
-56.2%
Peak to trough
ATR 14
0.85
3.88% of price
Beta (reported)
0.73
5Y monthly, from filing
Short interest
Shares short
5.68M
Prior 6.52M
Change vs prior
-13.0%
Shorts covering
% of float
20.82%
Heavily shorted
% of shares out
17.43%
Against total outstanding
Days to cover
6.7
Crowded exit
Float
30.35M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Oppenheimer | INITIATED | — | Outperform |
| Sep 9, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 19, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Aug 6, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 26 | Needham | MAINTAINED | Buy | Buy |
| Feb 26, 26 | Needham | MAINTAINED | Buy | Buy |
| Jan 9, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jan 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 8, 26 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K/A · 2026-06-30
Offering Registrations
S-8 · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-15
Corporate Changes & Voting Matters
8-K · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-07
Headlines
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
GlobeNewswire · 18h ago
3 Healthcare Stocks That Concern Us
StockStory · 7d ago
3 Value Stocks That Fall Short
StockStory · 9d ago
Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says
MT Newswires · 14d ago
Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target
MT Newswires · 14d ago
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
StockStory · 15d ago
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
StockStory · 16d ago
Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target
MT Newswires · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.